What RxMP Therapeutics does

RxMP Therapeutics is a privately held, late pre-clinical stage biopharmaceutical company developing a first-in-class hemostatic therapeutic, RMP-402, based on its proprietary red cell-derived microparticle (RMP) platform. RMPs are allogeneic red blood cell membrane particles manufactured via high-pressure extrusion of human packed red blood cells; RMP-402 is designed to be administered intravenously to rapidly arrest or prevent severe bleeding by enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation) without increasing the risk of off-target clotting. The company is pursuing both civilian healthcare applications (trauma centers, hospitals, surgical settings) and military/combat-casualty-care applications, and is in active discussions with the U.S. Department of Defense on a potential Emergency Use Authorization pathway.

The company's go-to-market model centers on enterprise field sales to hospitals, trauma centers, and military medical channels upon regulatory approval, with a one-time license/product-sale revenue model. To date, RxMP has no commercialized product and is pre-revenue; it has been funded primarily by approximately $11 million in grants and $5.5 million in equity investment, anchored by the Wallace H. Coulter Foundation as its largest shareholder, and opened a $2 million bridge financing round in December 2025. Strategic infrastructure includes an FDA consensus on its cGMP manufacturing process achieved in 2025, a CRADA with the DoD's Institute of Surgical Research for preclinical validation, and an April 2026 contract manufacturing partnership with OrganaBio for cGMP production. The company is led by founder/CEO Rifat Pamukcu and CSO Wenche Jy, both with multi-decade expertise in the underlying science.

Revenue economics remain entirely contingent on future regulatory approval and commercialization of RMP-402; the company is headquartered in Rancho Santa Fe, California, operates with 1–10 employees, and targets a global trauma and surgical bleeding market estimated at $12 billion annually.

Name

RxMP Therapeutics

Legal name

RxMP Therapeutics, Inc.

Website

https://rxmpt.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

RxMP Therapeutics is a late pre-clinical biopharmaceutical company developing RMP-402, a first-in-class intravenous hemostatic therapeutic based on proprietary red cell-derived microparticles, targeting severe bleeding in civilian trauma and military combat-casualty-care settings.

Ownership category

akta.pro rank

Product category

Hemostatic Pharmaceuticals

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Companion Animal Therapeutics (Rx) (HLAMAEAA)

akta.pro secondary industries

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics (HLAMANAB), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO), Condition-specific Digital Therapeutics (DTx) (HLACANAA)

Keywords

• Hemostatic therapeutics
• Hemorrhage control drugs
• Red blood cell microparticles
• Pharmaceutical drug development
• Trauma bleeding treatment

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue company. Future revenue expected from sale of RMP-402 hemostatic therapeutic product for severe hemorrhage control in civilian and military settings upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

RxMP Therapeutics is developing RMP-402, a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) designed to be administered intravenously to rapidly arrest or prevent severe bleeding without increasing the risk of off-target clotting. RMP-402 is being developed for severe hemorrhage control in civilian trauma centers and hospitals as well as for military combat casualty care, with a global trauma and surgical bleeding market estimated at $12 billion annually.

Product overview

RxMP Therapeutics is developing a novel hemostatic platform based on red cell-derived microparticles (RMPs). The company's lead product candidate, RMP-402, is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles designed to arrest or prevent excessive bleeding systemically. The technology is based on naturally occurring RMPs that support coagulation by serving as sites for the assembly of clotting factors and enhancing platelet function.

Differentiator

Problem solved

Functional benefit

Products and services

• RMP-402 Hemostatic Therapeutic RMP-402 is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) — analogs of particles that circulate naturally in human blood. It is administered intravenously and is designed to rapidly stop severe bleeding without increasing the risk of off-target clotting, enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation). It is being developed for both civilian healthcare (trauma centers, hospitals, surgical facilities) and military combat casualty care settings.

Quantifiable outcome

• Demonstrated efficacy in multiple animal models of bleeding and hemorrhage across species with high level of safety
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• OrganaBiocoreStrategic or Co-development Partner · 22 April 2026OrganaBio serves as RxMP's contract manufacturing partner for cGMP production of RMP-402. The agreement covers technology transfer, qualification, and cGMP production leveraging OrganaBio's integrated manufacturing infrastructure and quality management systems. This is a critical partnership for advancing the drug product through key development milestones toward regulatory approval.
• U.S. Department of Defense Institute of Surgical ResearchcoreStrategic or Co-development Partner · 1 March 2025RxMP entered into a Cooperative Research and Development Agreement (CRADA) with the Institute of Surgical Research, a subordinate federal laboratory of the Defense Health Agency within the DoD. Under the CRADA, RxMP provides RMP-402 and red cell-derived lyophilized microparticles to ISR for validation studies promoting coagulation function in large animal preclinical models of polytrauma hemorrhage and shock.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• CSL Behring: CSL Behring markets a broad portfolio of plasma-derived and recombinant coagulation products for hemophilia and surgical bleeding, overlapping with RxMP's target indications and representing a likely strategic acquirer in the hemostatic space.
• Octapharma: Octapharma is a major global plasma products manufacturer with a portfolio of coagulation factor concentrates and hemostatic therapies serving trauma, surgery and bleeding disorders, making it a broad incumbent competitor and potential strategic acquirer of RxMP.
• Grifols: Grifols produces plasma-derived coagulation factors and other hemostatic products for hospital and trauma use, directly overlapping with RxMP's civilian hospital/trauma-center target market and a credible strategic acquirer.
• Takeda Pharmaceutical: Takeda's rare bleeding disorder and hemophilia franchise (formerly Baxalta/Shire) competes in the same hospital and specialty hemostasis segments RxMP targets and serves as a benchmark strategic acquirer for late-stage hemostatic assets.
• Medicines Company / CSL Seqirus (tranexamic acid): The originator of intravenous tranexamic acid (TXA), currently the standard-of-care systemic hemostatic for trauma, represents RxMP's principal clinical comparator and incumbent in the trauma hemostasis market RxMP is targeting.

Emerging players

• Cerus Corporation: Cerus develops pathogen-reduced blood components and INTERCEPT-treated platelets and plasma used in transfusion and bleeding management, sharing the blood-component-based therapeutic approach with RxMP's red cell-derived platform.
• Velico Medical: Velico is developing spray-dried plasma and other blood-derived emergency hemostatic products for trauma use, a directly comparable early-stage approach to providing off-the-shelf hemostatic therapy in military and civilian settings.
• RevMedX: RevMedX develops advanced hemostatic devices (e.g., XSTAT, XGAUZE) used by the U.S. military and EMS for severe hemorrhage control, sharing RxMP's military and civilian trauma-channel focus.

Direct peers

• Cellphire Therapeutics: Cellphire is developing thrombosomes, a lyophilized platelet-derived hemostatic product for severe bleeding, the closest mechanistic analog to RxMP's red cell-derived microparticle approach and the most directly comparable hemostatic therapeutic peer.
• Haima Therapeutics: Haima is developing synthetic platelet-like particles for hemorrhage control, directly comparable to RxMP's synthetic red cell-derived microparticle platform in mechanism (mimicking natural hemostatic particles) and target indications (trauma, surgical bleeding).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rxmp-therapeutics-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxMP Therapeutics